[Cardiovascular disease in diabetes mellitus: classical and non-classical risk factors]
- PMID: 17505632
- DOI: 10.1590/s0004-27302007000200014
[Cardiovascular disease in diabetes mellitus: classical and non-classical risk factors]
Abstract
Cardiovascular disease, which includes coronary heart disease (CHD), cerebrovascular disease (CVD), and peripheral vascular disease (PVD), is the leading cause of mortality in populations, particularly in the diabetic one. Individuals with diabetes have at least a two-fold to four-fold increased risk of having cardiovascular events and a double risk of death compared with age-matched subjects without diabetes. A decline in mortality from CVD has been shown, but decline due to CHD is consistently lower in individuals with diabetes when compared with non-diabetics. The presence of several factors in diabetes leads to high occurrence of CVD such as hyperglycemia, insulin resistance, and classical and non-classical risk factors (systemic hypertension, dyslipidemia, obesity, proinflammatory condition and others). It is possible that the atherogenic role of obesity may be at least in part due to increased adipocyte production of cytokines. Considering the marked association of diabetes and CVD and unfavorable prognosis following an event, it is important to identify who is at high risk and how to screen. The American Heart Association and American Diabetes Association recommend risk stratification using diagnostic tests. However, the challenge is to accurately identify patients without a prior history of an event and those without symptoms strongly suggesting CVD, in whom additional testing would be indicated in order to achieve the most effective prevention. The benefits of glycemic control and the other risk factors have already been shown and justify optimization of the management of this high-risk population, aiming to reduce cardiovascular mortality disease and improve quality of life.
Similar articles
-
Cardiovascular disease risk in youth with diabetes mellitus.Rev Endocr Metab Disord. 2006 Sep;7(3):197-204. doi: 10.1007/s11154-006-9016-y. Rev Endocr Metab Disord. 2006. PMID: 17160723 Review.
-
Cardiovascular risk in diabetes: a brief review.J Diabetes Complications. 2000 Mar-Apr;14(2):108-15. doi: 10.1016/s1056-8727(00)00065-9. J Diabetes Complications. 2000. PMID: 10959073 Review.
-
Hypoglycemia, diabetes, and cardiovascular disease.Diabetes Technol Ther. 2012 Jun;14 Suppl 1(Suppl 1):S51-8. doi: 10.1089/dia.2012.0031. Diabetes Technol Ther. 2012. PMID: 22650225 Free PMC article. Review.
-
Influence of type 2 diabetes mellitus on cardiovascular disease mortality: findings from the Hawaii-Los Angeles-Hiroshima study.Diabetes Res Clin Pract. 2002 Jul;57(1):61-9. doi: 10.1016/s0168-8227(02)00016-5. Diabetes Res Clin Pract. 2002. PMID: 12007731
-
The role of IGF-I in the development of cardiovascular disease in type 2 diabetes mellitus: is prevention possible?Eur J Endocrinol. 2002 Apr;146(4):467-77. doi: 10.1530/eje.0.1460467. Eur J Endocrinol. 2002. PMID: 11916613 Review.
Cited by
-
Frailty and cardiovascular risk in community-dwelling elderly: a population-based study.Clin Interv Aging. 2014 Oct 6;9:1677-85. doi: 10.2147/CIA.S68642. eCollection 2014. Clin Interv Aging. 2014. PMID: 25336932 Free PMC article.
-
Association of endothelin-1 and matrix metallopeptidase-9 with metabolic syndrome in middle-aged and older adults.Diabetol Metab Syndr. 2015 Dec 10;7:111. doi: 10.1186/s13098-015-0108-2. eCollection 2015. Diabetol Metab Syndr. 2015. PMID: 26692905 Free PMC article.
-
Association of classical risk factors and coronary artery disease in type 2 diabetic patients submitted to coronary angiography.Diabetol Metab Syndr. 2014 Mar 29;6(1):46. doi: 10.1186/1758-5996-6-46. Diabetol Metab Syndr. 2014. PMID: 24678928 Free PMC article.
-
Prognosis of Coronary Artery Disease in Public Hospitals in Brazil: The ERICO Study and the Application of Knowledge in Public Health.Arq Bras Cardiol. 2021 Nov;117(5):986-987. doi: 10.36660/abc.20210825. Arq Bras Cardiol. 2021. PMID: 34817007 Free PMC article. English, Portuguese. No abstract available.
-
Semaglutide Attenuates Anxious and Depressive-Like Behaviors and Reverses the Cognitive Impairment in a Type 2 Diabetes Mellitus Mouse Model Via the Microbiota-Gut-Brain Axis.J Neuroimmune Pharmacol. 2024 Jul 23;19(1):36. doi: 10.1007/s11481-024-10142-w. J Neuroimmune Pharmacol. 2024. PMID: 39042202